I have published extensively in top peer reviewed scientific journals, mainly in the field of psychopharmacology.  Publishing scientific papers is an exceedingly tedious business — writing them is straightforward enough, but the process of submitting them on the Journal website can take days of work.  I had ceased doing it several years ago because of my disability and disinclination to engage with the increasingly onerous processes involved.

However, the assistance of several clever young people (CYPs), who now help me, has made it possible to translate more of my previous writing into peer reviewed papers, and also to start the International MAOI Expert Group, which has bought together many dozens of specialists interested in these drugs, from all over the world.  That has also led to the publication of the first ever authoritative guideline for the use of these drugs,which has now received more than 30,000 downloads, and it has been rated via altmetric as in the top 8% of 25 million papers — a spectacular success.

I therefore wish to publicly acknowledge the hard work of these CYPs who have made the more recent papers listed below possible.

My major reviews have covered various aspects of MAOIs, serotonin toxicity, the pharmacology of TCAs, and neuroleptic malignant syndrome.  

My profile on ‘Google Scholar’ shows current citation counts and ‘H-index’ (Hi-30).

Full PDFs are often available.

Publications Nov 2023

*2023 A.32 Phenelzine – treatment-resistant depression – EML. The role of classic Monoamine Oxidase Inhibitors in treatment-resistant depression: proposal for the inclusion of Phenelzine in the Complementary List of Essential Medicines. 

Van den Eynde, V., C. Redhead, L. Godet and P. K. Gillman

24th Expert Committee on Selection and Use of Essential Medicines: 68 pages.


*2023 Classic Monoamine Oxidase Inhibitors for Depression: Update on Nursing Care. 

Van den Eynde, V., L. Godet, S. Trupin and P. K. Gillman

Issues Ment Health Nurs 44(2): 138-139.



*2023 Classics in Chemical Neuroscience: Selegiline, Isocarboxazid, Phenelzine, and Tranylcypromine. 

Hoffman, G. R., M. G. Olson, A. M. Schoffstall, R. F. Estévez, V. Van den Eynde, P. K. Gillman and M. E. Stabio

ACS Chem Neurosci: in press.



*2023 Efficacy and safety of selegiline across different psychiatric disorders: A systematic review and meta-analysis of oral and transdermal formulations. 

Rossano, F., C. Caiazza, A. Sobrino, N. Solini, A. Vellucci, N. Zotti, M. Fornaro, K. Gillman, C. I. Cattaneo, V. Van den Eynde, T. K. Birkenhager, H. G. Ruhé, S. Stahl, F. Iasevoli and A. de Bartolomeis

European Neuropsychopharmacology 72: 60-78.


*2023 Expert opinion on anaesthetic considerations for patients receiving a classic monoamine oxidase inhibitor. 

Van den Eynde, V., H. Rosenbaum and P. K. Gillman

Anesthesia & Analgesia: in press.


*2023 An Expert Roundtable Discussion on the Use of Classic Monoamine Oxidase Inhibitors in the Treatment of Depression – Part One. 

Young, A., J. Rucker, V. Van den Eynde, C. Redhead, B. Barnett, L. Godet, A. Cleare, J. Cosgrove, S. Stahl, T. Birkenhäger and P. K. Gillman

Psychiatric Annals 53(8): 359-363.



*2023 An Expert Roundtable Discussion on the Use of Classic Monoamine Oxidase Inhibitors in the Treatment of Depression – Part Two. 

Berk, M., V. Van den Eynde, K. Ganapathy, C. Andrade, T. Birkenhäger, J. A. Bodkin, D. Nutt, B. Barnett, S. S. Feinberg, G. Parker, E. Ruhe, M. Fornaro, C. Redhead, L. Godet and P. K. Gillman

Psychiatric Annals 53(8): 364-369.



*2023 A five-pronged critique of “Serotonin syndome—A focused review”. 

Gillman, P. K. and V. Van den Eynde

Basic & Clinical Pharmacology & Toxicology.



*2023 MAOIs: Reconsideration and Re-education. 

Gillman, P. K. and V. Van den Eynde

Psychiatric Annals 53(8): 343-344.



*2023 Monoamine oxidase inhibitor interactions: an addendum to Dr. Shader’s letter. 

Gillman, P. K. and V. Van den Eynde

J Clin Psychopharmacol: In press.


*2023 Monoamine Oxidase Inhibitors and Clinically Relevant Drug Interactions: A Guide for Preventing Serotonin Toxicity and Hypertensive Reactions. 

Gillman, P. K., V. Van den Eynde, L. Godet, C. Redhead, A. Horwitz and B. Barnett

Psychiatric Annals 53(8): 353-358.



*2023 On the Origins of MAOI Misconceptions: Reaffirming their Role in Melancholic Depression. 

Van den Eynde, V., G. Parker, H. G. Ruhe, T. Birkenhäger, L. Godet, E. Shorter and P. K. Gillman

Psychopharmacology Bulletin 53(3): 35-54.


*2023 The Pocket Guide to Classic Monoamine Oxidase Inhibitors for Treatment-Resistant Depression. 

Stahl, S., V. Van den Eynde, L. Godet, C. Redhead and P. K. Gillman

Psychiatric Annals 53(8): 347-352.



*2022 Causality is the missing key: A comment on the history of MAOIs and RCTs. 

Van den Eynde, V. and P. K. Gillman

Journal of Affective Disorders 319: 670-671.


*2022 MAOI or ECT? Patient Preference and Joint Decision-Making in Treatment-Resistant Depression. 

Van den Eynde, V. and P. K. Gillman

Current Treatment Options in Psychiatry 9: 419-422.



*2022 Monoamine oxidase inhibitors: A review concerning dietary tyramine and drug interactions. 

Gillman, P. K.

PsychoTropical Commentaries 5: 1-43.


*2022 The prescriber’s guide to classic MAO inhibitors (phenelzine, tranylcypromine, isocarboxazid) for treatment-resistant depression. 

Van den Eynde, V., W. R. Abdelmoemin, M. M. Abraham, J. D. Amsterdam, I. M. Anderson, C. Andrade, G. B. Baker, A. T. F. Beekman, M. Berk, T. K. Birkenhäger, B. B. Blackwell, P. Blier, M. B. J. Blom, A. J. Bodkin, C. I. Cattaneo, B. Dantz, J. Davidson, B. W. Dunlop, R. F. Estévez, S. S. Feinberg, J. P. M. Finberg, L. J. Fochtmann, D. Gotlib, A. Holt, T. R. Insel, J. K. Larsen, R. Mago, D. B. Menkes, J. M. Meyer, D. J. Nutt, G. Parker, M. D. Rego, E. Richelson, H. G. Ruhé, J. Sáiz-Ruiz, S. M. Stahl, T. Steele, M. E. Thase, S. Ulrich, A. J. L. M. van Balkom, E. Vieta, I. Whyte, A. H. Young and P. K. Gillman

CNS Spectrums: 1-14.



*2022 The Prescriber’s Guide to the MAOI Diet-Thinking Through Tyramine Troubles. 

Van den Eynde, V., P. K. Gillman and B. B. Blackwell

Psychopharmacol Bull 52(2): 73-116.


*2022 Requiem or resurrection: Classic monoamine oxidase inhibitors revisited. 

Van den Eynde, V. and P. K. Gillman

European Neuropsychopharmacology 61: 15-16.


*2021 Het gebruik van klassieke monoamineoxidase-inhibitoren (MAOIs) bij therapieresistente depressie. Verplichte gegrondheidsvoorwaarde bij een euthanasievraag? 

Van den Eynde, V. and P. K. Gillman

Euthanasierecht in België – De wet in verandering(?): 363-371.


*2021 Prepared mind leads to life-saving medical advice. 

Ramsay, R. R. and P. K. Gillman

The American Society for Biochemistry and Molecular Biology:


*2020 A critial appraisal of ‘Hypertensive crisis following the administration of tedizolid: possible serotonin syndrome’. 

Van den Eynde, V. and P. K. Gillman

Eur J Hosp Pharm 27(1): 52-54.



*2020 The larger than linear effect of high-dose tyramine on systolic blood pressure – the MAOI diet modified. 

Van den Eynde, V. and P. K. Gillman

Int J Psychiatry Clin Pract 24(3): 328.



*2020 Requiem or resurrection? A motion for the reintroduction of tranylcypromine on the Belgian market. 

Van den Eynde, V. and P. K. Gillman

Acta Psychiatrica Belgica 120(2): 7-8.


*2019 A critical appraisal [Eletter in response to] Hypertensive crisis following the administration of tedizolid: possible serotonin syndrome. 

Van den Eynde, V. and P. K. Gillman

European Journal of Hospital Pharmacy:


*2019 Hypertensive crisis following the administration of tedizolid: possible serotonin syndrome. . 

Van den Eynde, V. and P. Gillman

European Journal of Hospital Pharmacy:


*2019 Revitalizing monoamine oxidase inhibitors: A call for action. 

Gillman, P. K., S. Feinberg and L. Fochtmann

CNS Spectrums 25(4): 452-454.


*2018 A reassesment of the safety profile of monoamine oxidase inhibitors: elucidating tired old tyramine myths. 

Gillman, P. K.

J Neural Transm (Vienna) 125(11): 1707-1717.



*2018 Update on recent serotonin toxicity publications including comment on, ‘Conundrums in neurology: Diagnosing serotonin syndrome – a meta-analysis of cases’. 

Gillman, P. K.

PsychoTropical Commentaries 18(8): 1-12.


*2017 “Much ado about nothing”: monoamine oxidase inhibitors, drug interactions, and dietary tyramine. 

Gillman, P. K.

CNS Spectr: 1-3.



*2016 Patient Safety and Methylene Blue-Associated Severe Serotonin Toxicity. 

Rosenbaum, H. and P. K. Gillman

A&A Case Reports 7(1).



*2014 Fatal methylene blue associated serotonin toxicity. 

Top, W. M., P. K. Gillman, C. J. de Langen and A. Kooy

Neth J Med 72(3): 179-181.


*2013 Atypical antipsychotics: where is the science, where is the evidence? 

Gillman, P. K.

The Carlat Psychiatry Report 11(1): 3-5.


*2012 Methylene blue and serotonin reuptake inhibitors – an update. 

Gillman, P. K.

Australian and New Zealand College of Anaesthetists Bulletin June: 43.


*2011 Advances pertaining to the pharmacology and interactions of irreversible nonselective monoamine oxidase inhibitors. 

Gillman, P. K.

Journal of Clinical Psychopharmacology 31(1): 66-74.


00004714-201102000-00013 [pii]


*2011 CNS toxicity involving methylene blue: the exemplar for understanding and predicting drug interactions that precipitate serotonin toxicity. 

Gillman, P. K.

Journal of Psychopharmacology 25(3): 429-423.



*2011 Pharmacology of MAO-B inhibitors and the cheese reaction. 

Finberg, J. and P. Gillman

International Review of Neurobiology 100: 169-190.


*2010 Bupropion, Bayesian logic and Serotonin Toxicity. 

Gillman, P. K.

Medical Toxicology 6: 276-277.



*2010 Combining antidepressants: Understanding Drug Interactions is the Sine Qua Non. 

Gillman, P. K.

Advances in Psychiatric Treatment 16: 76-78.



*2010 Hyperthermic Fatalities of Uncertain Cause. 

Gillman, P. K.

Neuropathology 31: 306–307 (published online: 314 Mar 2011).

DOI: 10.1111/j.1440-1789.2010.01187.x


*2010 In Reference to Parathyroid Surgery and Methylene Blue: a Review with Guidelines for Safe Intraoperative Use. 

Gillman, P. K.

Laryngoscope 120(2): 436-437.


*2010 Interaction of temperature regulation mechanisms. 

Gillman, P. K.

Lancet 376(9737): 233-234.

S0140-6736(10)61144-0 [pii]



*2010 Methylene Blue and Serotonin Toxicity: Definite Causal Link. 

Gillman, P. K.

Psychosomatics 51(5): 448-449.


*2010 Multiple triggers for NMS. 

Gillman, P. K.

Australas Psychiatry 18(3): 266.



*2010 The Nature of Hyperthermia in Neuroleptic Malignant Syndrome and the Use of Bromocriptine. 

Gillman, P. K.

J Med Toxicol 6: 272–273.



*2010 Neuroleptic malignant syndrome, poor science and inaccurate measurements. 

Gillman, P. K.

Journal of Psychopharmacology: 20 May 2010, 2010.1177/0269881110367461.

0269881110367461 [pii]



*2010 Neuroleptic malignant syndrome: half a century of uncertainty suggests a Chimera. 

Gillman, P. K.

Pharmacoepidemiology and Drug Safety 19(8): 876-877.



*2010 Neuroleptic Malignant Syndrome: Mechanisms, Interactions and Causality. 

Gillman, P. K.

Movement Disorders 25(12): 1780-1790.



*2009 Fentanyl and serotonin toxicity. 

Gillman, P. K.

British Journal of Anaesthesia:


*2009 In response to Morris et al.’s “Neuroleptic malignant syndrome developing after acute overdose with olanzapine and chlorpromazine”. 

Gillman, K.

Journal of Medical Toxicology 5(4): 259-259.


*2009 Is there sufficient evidence to suggest cyclobenzaprine might be implicated in causing serotonin toxicity? 

Gillman, P. K.

American Journal of Emergency Medicine 27(4): 509-510.


*2009 Lessons continue: serotonin toxicity. 

Gillman, P. K.

Consulting Pharmacy 24: 398-399.


*2009 Mechanisms, management and measurement in atropine induced hyperthermia. 

Gillman, P. K.

Anaesthesia and Intensive Care 37(2): 322-323.


*2009 Risk of severe serotonin toxicity following co-administration of methylene blue and serotonin reuptake inhibitors: an update on a case report of post-operative delirium. 

Stanford, S. C., B. J. Stanford and P. K. Gillman

Journal of Psychopharmacology 24(10): 1433-1438.


*2009 Small doses of methylene blue, previously considered safe, can precipitate serotonin toxicity. 

Schwiebert, C., C. Irving and P. K. Gillman

Anaesthesia 64: 924-924.


*2009 Triptans, Serotonin Agonists, and Serotonin Syndrome (Serotonin Toxicity): A Review. 

Gillman, P. K.

Headache 50(2): 264-272.



*2008 Methylene blue is a potent monoamine oxidase inhibitor. 

Gillman, P. K.

Can J Anaesth 55(5): 311-312.


*2007 Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. 

Ramsay, R. R., C. Dunford and P. K. Gillman

Br J Pharmacol 152(6): 946-951.



*2007 Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. 

Gillman, P. K.

British Journal of Pharmacology 151(6): 737-748.



*2006 Beware of anticholinergics in the elderly: delirious dangers of the deadly nightshade. 

Peterson, G., S. Jackson, M. Naunton and P. K. Gillman

Journal of Pharmacy 25: 882-884.


*2006 Extracting value from case reports: lessons from serotonin toxicity. 

Gillman, P. K.

Anaesthesia 61: 419-422.


*2006 Methylene Blue implicated in potentially fatal serotonin toxicity. 

Gillman, P. K.

Anaesthesia 61: 1013-1014.


*2006 A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action. 

Gillman, P. K.

Biological Psychiatry 59(11): 1046-1051.


*2006 Serotonin Toxicity Associated with the Use of Linezolid: A Review of Postmarketing Data. 

Lawrence, K. R., M. Adra and P. K. Gillman

Clinical infectious diseases 42: 1578-1583.


*2006 A systematic review of the serotonergic effects of mirtazapine: implications for its dual action status. 

Gillman, P. K.

Human Psychopharmacology. Clinical and Experimental 21(2): 117-125.


*2005 Drug interactions and fluoxetine: a commentary from a clinician’s perspective. 

Gillman, P. K.

Ex Op Drug Saf 4: 965-969.



*2005 Misleading cases. 

Gillman, P. K.

Journal of the American Medical Directors Association 6: 422-423.



*2005 Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. 

Gillman, P. K.

British Journal of Anaesthesia 95(4): 434-441.



*2005 More misleading case reports. 

Gillman, P. K.



*2005 NMS and ST: chalk and cheese. 

Gillman, P. K.

British Medical Journal:


*2005 Understanding toxidromes: serotonin toxicity. A commentary on Montanes-Rada et al. 

Gillman, P. K.

Journal of Clinical Psychopharmacology 25: 625-626.



*2004 Defining toxidromes: serotonin toxicity and neuroleptic malignant syndrome: A comment on Kontaxakis et al. 

Gillman, P. K.

Archives of General Hospital Psychiatry:


*2004 Making sense of serotonin toxicity reports. A comment on Chopra et al. 

Gillman, P. K.

World Journal of Biological Psychiatry 5: 166-167.



*2004 Moclobemide and the risk of serotonin toxicity (or serotonin syndrome). 

Gillman, P. K.

Central Nervous System Drug Reviews 10: 83-85.



*Gillman, P. K. and I. M. Whyte (2004). Serotonin syndrome. Adverse Syndromes and Psychiatric Drugs. P. Haddad, S. Dursun and B. Deakin. Oxford, Oxford University Press: 37-49.


*2004 The spectrum concept of serotonin toxicity. 

Gillman, P. K.

Pain Medicine 5: 231-232.


*2003 Amitriptyline: Dual-Action Antidepressant? 

Gillman, P. K.

Journal of Clinical Psychiatry 64: 1391.


*2003 Linezolid and serotonin toxicity. 

Gillman, P. K.

Clinical infectious diseases 37: 1274-1275.



*2003 Mirtazapine: unable to induce serotonin toxicity? 

Gillman, P. K.

Clinical Neuropharmacology 26: 288-289.



*1999 Commentary: clomipramine too soon after moclobemide. 

Gillman, P. K.

Review of Psychiatry 4: 3-5.


*1999 Relative toxicity of antidepressants. 

Gillman, P. K.

Australian and New Zealand Journal of Psychiatry 33: 444.


*1999 The serotonin syndrome and its treatment. 

Gillman, P. K.

Journal of Psychopharmacology 13(1): 100-109.



*1998 Serotonin syndrome following SSRI mono-therapy. 

Gillman, P. K. and S. Hodgens

Human Psychopharmacology. Clinical and Experimental 13: 525-526.


*1998 Serotonin Syndrome: History and Risk. 

Gillman, P. K.

Fundamental and Clinical Pharmacology 12(5): 482-491.



*1997 Ecstasy, serotonin syndrome and the treatment of hyperpyrexia. 

Gillman, P. K.

Medical Journal of Australia 167: 109-111.


*1997 Serotonin syndrome treated with chlorpromazine. 

Gillman, P. K.

Journal of Clinical Psychopharmacology 17: 128-129.


*1997 Serotonin syndrome: clomipramine too soon after moclobemide. 

Gillman, P. K.

International Clinical Psychopharmacology 12: 339-342.


*1996 Successful treatment of serotonin syndrome with chlorpromazine. 

Gillman, P. K.

Medical Journal of Australia 165: 345.


*1995 Possible serotonin syndrome with moclobemide and pethidine. 

Gillman, P. K.

Medical Journal of Australia 162: 554.


*1994 MAOIs and dangerousness. 

Gillman, P. K.

Australian Prescriber 17(2): 29.


*1980 Decreased conjugated tyramine output in depression: the effect of oral L-cysteine. 

Carter, S. M., B. L. Goodwin, M. Sandler, P. K. Gillman and P. K. Bridges

British Journal of Clinical Pharmacology 10(3): 305-308.


*1980 Relationships between tryptophan concentrations in human plasma, cerebrospinal fluid and cerebral cortex following tryptophan infusion. 

Gillman, P. K., J. R. Bartlett, P. K. Bridges, B. D. Kantamaneni and G. Curzon

Neuropharmacology 19(12): 1241-1242.


*1980 Substances related to 5-hydroxytryptamine in plasma and in lumbar and ventricular fluids of psychiatric patients. 

Curzon, G., B. D. Kantamaneni, P. Van Boxel, P. K. Gillman, J. R. Bartlett and P. K. Bridges

Acta Psychiatrica Scandinavica 280: 3-20.



Share This Page

Consider Donating to PsychoTropical

PsychoTropical is funded solely through generous donations, which has enabled extensive development and improvement of all associated activities. Many people who follow the advice on the website will save enormously on doctors, treatment costs, hospitalization, etc. which in some cases will amount to many thousands of dollars, even tens of thousands — never mind all the reduction in suffering and the resultant destruction of family, work, social, and leisure capability. A donation of $100, or $500, is little compared to those savings. Some less-advantaged people feel that the little they can give is so small it won’t make a difference – but five dollars monthly helps: so, do not think that a little donation is not useful.

– Dr Ken Gillman

Dr Ken Gillman